Catheter Evaluation for Endocardial Ablation in Patients With Typical Atrial Flutter

NCT ID: NCT00318565

Last Updated: 2012-03-05

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

291 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2008-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to provide additional corroborative safety and efficacy data for the Navistar Thermocool catheter for the treatment of subjects with typical atrial flutter (AFL).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a prospective, non-randomized, single-arm, multi-center condition of approval evaluation. The device is currently FDA approved for commercial distribution. Subjects with symptomatic typical atrial flutter will be considered for the condition of approval study. This study will be conducted at up to 30 centers in a minimum of 221 evaluable subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Flutter

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Navistar ThermoCool Catheter

Group Type EXPERIMENTAL

RF energy delivery for treatment of Typical Atrial flutter

Intervention Type DEVICE

Navistar ThermoCool catheter

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RF energy delivery for treatment of Typical Atrial flutter

Navistar ThermoCool catheter

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Therapeutic Catheters

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Two symptomatic episodes of typical atrial flutter (or chronic atrial flutter) during the one-year period prior to enrollment. This may include typical AFL occurring while receiving anti-arrhythmic drug (AAD) therapy for non-AFL tachyarrhythmia, including atrial fibrillation.
* At least one episode of typical (clockwise or counterclockwise) atrial flutter documented by 12 lead electrocardiogram (ECG), Holter monitor, transtelephonic event monitor, telemetry strip, or implanted device within 6 months prior to enrollment.
* 18 years of age or older
* Informed consent

Exclusion Criteria

* Intracardiac thrombus
* Uncontrolled heart failure, or New York Heart Association (NYHA) class III or IV heart failure
* Women who are pregnant
* Cardiac surgery (ventriculotomy or atriotomy) within the past two months
* Intra-atrial thrombus, tumor, or other abnormality that precludes catheter introduction and placement
* Unstable angina or acute myocardial infarction within 3 months
* Awaiting cardiac transplantation
* Heart disease in which corrective surgery is anticipated within 6 months
* Presence of condition that precludes appropriate vascular access
* Enrolled in any investigational device exemption (IDE) investigating study for a device or drug
* High risk for non-compliance with the protocol (e.g., inaccessible for follow-up by the investigator or patient's physician)
* Radio frequency (RF) ablation for typical atrial flutter within the past 2 months
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biosense Webster, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Warren Jackman, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Oklahoma

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama, Birmingham

Birmingham, Alabama, United States

Site Status

Arizona Arrhythmia Consultants

Scottsdale, Arizona, United States

Site Status

Good Samaritan Hospital

Los Angeles, California, United States

Site Status

Pacific Heart Institute

Santa Monica, California, United States

Site Status

University of Florida

Gainsville, Florida, United States

Site Status

Memorial Regional Hospital

Hollywood, Florida, United States

Site Status

Florida Hospital

Orlando, Florida, United States

Site Status

University of Chicago

Chicago, Illinois, United States

Site Status

The Care Group LLC, St. Vincent Hospital and Health Care Center, Inc.

Indianapolis, Indiana, United States

Site Status

Central Baptist Hospital

Lexington, Kentucky, United States

Site Status

Maine Medical Center

Portland, Maine, United States

Site Status

University of Maryland

Baltimore, Maryland, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

St. John Hospital and Medical Center

Detroit, Michigan, United States

Site Status

Park Nicollet Institute

Minneapolis, Minnesota, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

University of Oklahoma, Health Sciences Center

Oklahoma City, Oklahoma, United States

Site Status

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Texas Heart Institute

Houston, Texas, United States

Site Status

University of Vermont, College of Medicine

Burlington, Vermont, United States

Site Status

INOVA Research Center

Falls Church, Virginia, United States

Site Status

Virginia Commonwealth University

Richmond, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BWI30031

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Atrial Flutter Ablation in the iCMR
NCT05904548 RECRUITING NA